Numerous clinical studies have also confirmed that the enrichment of CD8+ T cells indicates a good prognosis for patients with CRC and the potential of benefiting from ICIs treatment.36–39 Extraction of MSS CRC samples from TCGA database (mRNA expression data) also confirmed that high expression of PD-L1 predicted a better antitumor immune cell infiltration. This evidence concerns the gene CD8A and colorectal carcinoma.